This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KENIGSBERG, D. Articles by HODGEN, G. D. Search for Related Content PubMed PubMed Citation Articles by KENIGSBERG, D. Articles by HODGEN, G. D.

Ovulation Inhibition by Administration of Weekly Gonadotropin-Releasing Hormone Antagonist

Department of Obstetrics and Gynecology, State University of New York at Stony Brook, School of Medicine Stony Brook, New York 11794-8091
Jones Institute for Reproductive Medicine and Department of Obstetrics and Gynecology, Eastern Virginia Medical School Norfolk, Virginia 23507

Address requests for reprints to: Dr. Gary D. Hodgen, Scientific Director, Jones Institute for Reproductive Medicine, Lewis Hall, Room 2011, Eastern Virginia Medical School, Norfolk, Virginia 23507.

To test the feasibility of administering the GnRH antagonist [(Ac-pClPhe¹,pCloPhe²,DTrp³,DArg⁶,DAla¹⁰)- GnRH] intermittently to inhibit ovulation, this agent was given to normal ovulatory cynomolgus monkeys once weekly for 4 weeks. Ovulation was blocked in all females (eight of eight) throughout the 32 study weeks and resumed within 14.3 ± 3.8 (±SEM) days in six of eight primates. Interestingly, mean tonic serum estradiol levels were not significantly reduced during treatment. Conversely, although midcycle levels of estradiol were not found, moderate estradiol levels occurred but they did not elicit preovulatory LH surges during the week after GnRH antagonist injection. In a second study directed at clarifying the mechanism(s) by which estrogen-induced LH surges were blocked, monkeys received GnRH antagonist in the early through the midfollicular phase of the menstrual cycle during which an estrogen (n = 3) or a GnRH (n = 4) challenge test was given on cycle day 6. Among monkeys receiving estradiol benzoate or a bolus dose of GnRH during the GnRH antagonist regimen, only those given GnRH (four of four monkeys) had increased LH secretion. These responses were similar to those of control monkeys (n = 3). Indeed, the pituitary was refractory (three of three monkeys) to estrogen-positive feedback for the LH surge. These findings indicate the potential utility of intermittent GnRH antagonist treatment to achieve contraception by ovulation inhibition, without creating a severely hypoestrogenic milieu attendant with the risks of negative sequelae effecting bone calcium loss, hot flushes, and atrophy of estrogendependent genital tissues.

^* Recipient, National Fellowship in Reproductive Medicine, Pregnancy Research Branch, NICHHD, NIH.

Received July 26, 1985.

This article has been cited by other articles:

				K. Gordon, R. T. Scott, R. F. Williams, D. R. Danforth, H. J. J. Loozen, H. J. Kloosterboer, and G. D. Hodgen In Vivo Effects of a Potent GnRH Antagonist ORG 30850: Physiologic Evidence That Down-Regulation of GnRH Receptors Does Not Occur Reproductive Sciences, October 1, 1994; 1(4): 290 - 296. [Abstract] [PDF]